focused on the development and commercialization of radiopharmaceutical theranostics and automated synthesizer & functional modules for radiopharmaceutical production in both R&D and GMP settings.

Founded in July 2021, NORROY has developed more than 7 pipelines currently under clinical investigations in solid tumors, include urological cancers, gastrointestinal & pancreatic cancers, lung cancers, breast & ovarian cancers, nasopharyngeal cancers, etc. In addition to innovation of radiopharmaceuticals pipelines and automated modules, NORROY also continues to establish a solid global supply of multiple radioisotopes, build commercial GMP manufacturing facilities and global distribution network with international partners.

Up to date, NORROY has received 4 IND clearance from the U.S. Food and Drug Administration (FDA), and 4 IND approvals from the National Medical Products Administration (NMPA). Recently, NORRY works closely with the regulatory agencies to advance its late-stage portfolios through internationally registered clinical trial investigations.